Clinical trials: Monoclonal

Clear-Cell Renal Carcinoma

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

• Terminated
• Age: 18 years and older
• Phase 2
• Results posted

Background: -Clear-cell renal cell carcinoma (ccRCC) is a kind of kidney cancer. The drug avelumab may help direct the immune response to the tumors and can prolong the immune response.

Trial name

NCT04150562

Testing

rhIL-15, Avelumab

Where

United States

Volunteers

2 people

Sponsor

National Cancer Institute (NCI)